$XBI $118.22 +1.46%%
Covid Updates
$PFE -1.4% & $BNTX -1.7% Pfizer and BioNTech Submit Updated Longer-Term Follow-Up Data of COMIRNATY® in Adolescents 12 Through 15 Years of Age to EMA. source
$AZN -0.8% Vaxzevria significantly boosted antibody levels against Omicron. source
$AZN -0.8% Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities. source
$GILD +0.1% Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19. source
Pipeline Updates
$XXII +38.6% FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product. source
$RDUS +2.0% Radius Announces Update on TYMLOS® (abaloparatide) Label. source
$VLON +0.5% Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR. source
$OPK +0.3% OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients. source
$EVLO -15.1% Planned updates to the study protocol for its Phase 2 clinical trial of EDP1815 in atopic dermatitis. source
Business Updates
$ENDP +2.9% Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims. source
$OMER +1.5% OMEROS COMPLETES SALE OF OMIDRIA® FRANCHISE TO RAYNER SURGICAL. source
$SAVA 1.4% Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease. source
$HZNP +1.1% Horizon Therapeutics plc to Participate in Upcoming Investor Conferences (JPM22). source
$ARQT +8.4% Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners. source
$TSHA -3.2% TAYSHA GENE THERAPIES ADDED TO THE ICE BIOTECHNOLOGY INDEX. source
$ENDP +2.9% Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada. source
$ADAG +1.4% Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates. source
$TBPH +1.6% License and collaboration agreement with Janssen for izencitinib terminated by Janssen. source
$TVTX +2.3% Entered into a Commercial Supply Agreement with Catalent, with an effective date of December 16, 2021, pursuant to which Catalent has agreed to provide certain services to the Company in connection with the processing and packaging of sparsentan tablets and primary packaging, intended for future commercial sale, if approved. source
Posted by DV/FS
Comments